inh

INH154 is a highly potent inhibitor of Nek2 and Hec1 binding (INH), with IC50 values of 120 nM in MB468 cells and 200 nM in Hela cells.

INH1 (IBT13131) is a cell-permeable Hec1 inhibitor that specifically disrupts the Hec1/Nek2 interaction.

RNF5 inhibitor inh-02 is a selective inhibitor of the ubiquitin ligase RNF5/RMA1, which can significantly rescue F508del-CFTR (cystic fibrosis transmembrane conductance regulator with a deletion at position 508 of phenylalanine) and regulate ATG4B and paxillin, making it useful for studying cystic fibrosis (CF).

INH14 is a novel inhibitor of the IKKα/β-dependent TLR inflammatory response (IC50s: 8.97/3.59 μM for IKKα/IKKβ).

INH6, an effective Hec1 inhibitor, selectively disrupts the Hec1/Nek2 interaction and induces chromosome mis-alignment.

INH-13 is a Aurora inhibitor.

CFTR(inh)-172 (CFTR Inhibitor-172) is a voltage-independent, selective CFTR inhibitor.

Isoniazid (Isonicotinic hydrazide) is an antibacterial agent used primarily as a tuberculostatic.

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM, demonstrating approximately 3,700-fold greater selectivity for Aurora B over Aurora A.

MK-8712 is a monobactam beta-lactamase inhibitor.

Isoniazid-d4 is a deuterium isotope marker for Isoniazid, which can be used for isotope tracing and drug metabolism studies.Isoniazid is a prodrug that must be activated by the bacterial peroxidase KatG, and is bactericidal against rapidly dividing Mycobacterium species.

Isoniazid-KLH is a hapten–carrier protein conjugate generated by chemically coupling Isoniazid to keyhole limpet hemocyanin (KLH), in which Isoniazid acts as a low-molecular-weight hapten that cannot induce an immune response on its own and must be conjugated to a macromolecular carrier protein to become immunogenic, thereby enabling its use in antibody generation, immunological detection systems, and experimental studies focused on drug-specific immune recognition and assay development.

Isoniazid-BSA is a hapten-carrier protein conjugate formed by binding isoniazid to BSA (bovine serum albumin). It enhances isoniazid-induced immune responses by combining a hapten with a protein adjuvant, commonly used in vaccine or antibody preparation research.

T16A(inh)-B01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class B inhibitor.

T16A(inh)-C01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class C inhibitor.

T16A(inh)-D01 is the Ca(2+)-activated Cl(-) Channel, Ano1 class D inhibitor.

UTA1inh-A1 is a novel inhibitor of kidney urea transporter UT-A1.

UTA1inh-B1 is a novel inhibitor of kidney urea transporter UT-A1.

UTA1inh-C1 is a novel inhibitor of kidney urea transporter UT-A1.

UTA1inh-D1 is a novel inhibitor of kidney urea transporter UT-A1 .

ODN INH-1, a palindromic and class R ('restricted') inhibitory ODN, is a potent inhibitor of TLR9-induced B cells and macrophages.

Inh2-B1 is an inhibitor targeting STK1 (Ser/Thr protein kinase) by directly binding to its ATP-binding catalytic domain. STK1 is a crucial component in the cell wall biosynthesis of Staphylococcus aureus and a key factor in MRSA resistance. Consequently, Inh2-B1 is regarded as an "antibiotic resistance breaker" with the ability to prevent biofilm formation.

PAT1inh-B01 hydrochloride is a selective SLC26A6 inhibitor. It inhibits the anion exchange mediated by PAT1 (Cl-/HCO3- exchanger) with an IC50 of 350 nM. This compound blocks fluid absorption in the small intestine and can be used for research into diseases related to insufficient intestinal secretion.

PAT1inh-B01, a selective SLC26A6 inhibitor, impedes PAT1 (a Cl-/HCO3- exchanger) activity, with an IC50 of 350 nM, effectively inhibiting anion exchange. It also obstructs fluid absorption in the small intestine and is utilized in the study of small intestinal hyposecretory disorders [1].